A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients

T. J. Babineau, A. Hackford, A. Kenler, B. Bistrian, R. A. Forse, P. G. Fairchild, S. Heard, M. Keroack, P. Caushaj and P. Benotti
Department of Surgery, Deaconess Hospital, Harvard Medical School, Boston.

OBJECTIVE: To examine the safety and efficacy of multiple doses of PGG-glucan (poly-[1-6]-B-D-glucopyranosyl-[1-3]-B-D-glucopyranose) in high-risk patients undergoing major thoracic or abdominal surgery. DESIGN: An interventional, multicenter, double-blind, randomized, placebo-controlled study. SETTING: Four university-affiliated medical centers. PATIENTS: Sixty-seven high-risk patients undergoing major thoracic or abdominal surgery. INTERVENTION: Patients were randomized in a 1:1:1:1 ratio to receive saline placebo or PGG-glucan at a dose of 0.1 mg/kg, 0.5 mg/kg, and 1.0 mg/kg or 2.0 mg/kg. One dose was administered before surgery and three doses were administered after surgery. MAIN OUTCOME MEASURES: To examine the safety and efficacy of PGG-glucan infusion and to identify potentially important factors for a planned phase III study. RESULTS: A dose-response trend with regard to infection incidence among patients who received PGG-glucan was observed. Serious infections occurred in four patients who received placebo and in three patients who received PGG-glucan at a dose of 0.1 mg/kg. However, only one patient who received PGG-glucan at a high dose had a serious infection. The incidence and severity of adverse events was comparable in all groups. CONCLUSIONS: PGG-glucan was generally safe and well tolerated, may decrease postoperative infection rates, and warrants further investigation in a planned phase III trial.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The effect of PGG-{beta}-glucan on neutrophil chemotaxis in vivo
LeBlanc et al.
J. Leukoc. Biol. 2006;79:667-675.
ABSTRACT | FULL TEXT  

The Lectin-Like Domain of Complement Receptor 3 Protects Endothelial Barrier Function from Activated Neutrophils
Tsikitis et al.
J. Immunol. 2004;173:1284-1291.
ABSTRACT | FULL TEXT  

Polysaccharide Immunomodulators as Therapeutic Agents: Structural Aspects and Biologic Function
Tzianabos
Clin. Microbiol. Rev. 2000;13:523-533.
ABSTRACT | FULL TEXT  

The influence of glucan polymer structure and solution conformation on binding to (1->3)-{beta}-D-glucan receptors in a human monocyte-like cell line
Mueller et al.
Glycobiology 2000;10:339-346.
ABSTRACT | FULL TEXT  

Effect of PGG-glucan on the Rate of Serious Postoperative Infection or Death Observed After High-Risk Gastrointestinal Operations
Dellinger et al.
Arch Surg 1999;134:977-983.
ABSTRACT | FULL TEXT  

Modulation of Endotoxin- and Enterotoxin-Induced Cytokine Release by In Vivo Treatment with beta -(1,6)-Branched beta -(1,3)-Glucan
Soltys and Quinn
Infect. Immun. 1999;67:244-252.
ABSTRACT | FULL TEXT  

A Novel Carbohydrate-Glycosphingolipid Interaction between a beta -(1-3)-Glucan Immunomodulator, PGG-glucan, and Lactosylceramide of Human Leukocytes
Zimmerman et al.
J. Biol. Chem. 1998;273:22014-22020.
ABSTRACT | FULL TEXT  

Prophylactic Anti-Infective Activity of Poly-[1-6]-beta -D-Glucopyranosyl-[1-3]-beta -D-Glucopyranose Glucan in a Guinea Pig Model of Staphylococcal Wound Infection
Kernodle et al.
Antimicrob. Agents Chemother. 1998;42:545-549.
ABSTRACT | FULL TEXT  

Utilization of a chromogenic Limulus amebocyte lysate blood assay in a multi-center study of sepsis
Ketchum et al.
Innate Immunity 1997;4:9-16.
ABSTRACT  

Preclinical and clinical evaluation of carbohydrate immunopharmaceuticals in the prevention of sepsis and septic sequelae
Williams et al.
Innate Immunity 1995;2:203-208.
ABSTRACT